STAAR Surgical Q3 preliminary sales up 6.9% to $94.7 million on China shipment
STAAR Surgical released preliminary third-quarter 2025 net sales of $94.7 million, up 6.9% from $88.6 million a year earlier, ahead of its October 23, 2025 stockholder vote on the Alcon merger proposal. The increase relied heavily on a $25.9 million December 2024 China shipment paid in full in the quarter, while distributor orders in China fell and nine-month sales declined year over year. The figures are unaudited and subject to change before the 10-Q is filed.
Key points
- Q3 2025 preliminary net sales of $94.7 million, up 6.9% from $88.6 million
- $25.9 million from the December 2024 China shipment was recognized in Q3 2025 after payment in full
- Net sales outside China grew 7.7%, while new orders from China distributors were lower
- Nine-month 2025 sales were lower than the prior year, as China distributors reduced inventory by about $80 million to $85 million
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.